5 trends tracked about this subject — the full history, oldest to newest below.
A 10-year study suggests that increasing fruit and vegetable intake may improve outcomes and reduce hospitalizations for kidney disease patients.
Novo Nordisk faces a divergent clinical outlook as its pediatric obesity trials succeed while heart drug programs for CKD suffer setbacks.
Novo Nordisk has terminated two additional phase 3 trials of its cardiovascular drug ziltivekimab due to futility, impacting its growth strategy.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Novo Nordisk faces a significant setback in expanding beyond obesity as a key phase 3 trial delivers disappointing results.